Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease

被引:1
|
作者
Yu, Hongsheng [1 ,2 ]
Huang, Yinan [1 ,2 ]
Li, Mingkai [1 ,2 ]
Jiang, Hao [1 ,2 ]
Yang, Bilan [3 ]
Xi, Xiaoli [1 ,2 ]
Smayi, Abdukyamu [1 ,2 ]
Wu, Bin [1 ,2 ]
Yang, Yidong [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Gastroenterol, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[2] Guangdong Prov Key Lab Liver Dis Res, Guangzhou, Peoples R China
[3] Sun Yat sen Univ, Affiliated Hosp 8, Dept Gastrointestinal Endoscopy Ctr, Shenzhen 518033, Peoples R China
基金
中国国家自然科学基金;
关键词
chronic hepatitis B; compensated advanced chronic liver disease; FibroScan; liver-related events; prognosis; HEPATOCELLULAR-CARCINOMA; ANTIVIRAL TREATMENT; RISK; FIBROSIS; PREDICTS; THERAPY; PROGRESSION; BIOPSY; MODEL;
D O I
10.1111/jgh.16673
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimLiver stiffness measurements (LSMs) are promising for monitoring disease progression or regression. We assessed the prognostic significance of dynamic changes in LSM over time on liver-related events (LREs) and death in patients with chronic hepatitis B (CHB) and compensated advanced chronic liver disease (cACLD).MethodsThis retrospective study included 1272 patients with CHB and cACLD who underwent at least two measurements, including LSM and fibrosis score based on four factors (FIB-4). Delta LSM was defined as [(follow-up LSM - baseline LSM)/baseline LSM x 100]. We recorded LREs and all-cause mortality during a median follow-up time of 46 months. Hazard ratios (HRs) and confidence intervals (CIs) for outcomes were calculated using Cox regression.ResultsBaseline FIB-4, baseline LSM, Delta FIB-4, Delta LSM, and Delta LSM/year were independently and simultaneously associated with LREs (adjusted HR, 1.04, 95% CI, 1.00-1.07; 1.02, 95% CI, 1.01-1.03; 1.06, 95% CI, 1.03-1.09; 1.96, 95% CI, 1.63-2.35, 1.02, 95% CI, 1.01-1.04, respectively). The baseline LSM combined with the Delta LSM achieved the highest Harrell's C (0.751), integrated AUC (0.776), and time-dependent AUC (0.737) for LREs. Using baseline LSM and Delta LSM, we proposed a risk stratification method to improve clinical applications. The risk proposed stratification based on LSM performed well in terms of prognosis: low risk (n = 390; reference), intermediate risk (n = 446; HR = 3.38), high risk (n = 272; HR = 5.64), and extremely high risk (n = 164; HR = 11.11).ConclusionsBaseline and repeated noninvasive tests measurement allow risk stratification of patients with CHB and cACLD. Combining baseline and dynamic changes in the LSM improves prognostic prediction. image
引用
收藏
页码:2169 / 2181
页数:13
相关论文
共 50 条
  • [41] Liver Stiffness Measurement can Predict Liver Inflammation in Chronic Hepatitis B Patients with Normal Alanine Transaminase
    Huang, Ling-Ling
    Yu, Xue-Ping
    Ruan, Qing-Fa
    Lin, Yan-Xue
    Li, Huan
    Jin, Wen
    Liu, Rui-Feng
    Liang, Yan-Lan
    Liu, Yu-Rui
    Zhu, Yue-Yong
    Jiang, Jia-Ji
    Mao, Ri-Cheng
    Zeng, Da-Wu
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2023, 11 (04) : 817 - 826
  • [42] Antiviral therapy for chronic hepatitis B and advanced liver disease
    Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2 (1): : 6 - 7
  • [43] Hepatitis A and hepatitis B vaccination of patients with chronic liver disease
    Bell, BP
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2000, 63 (04) : 359 - 363
  • [44] Dynamics of liver stiffness measurements provide incremental prognostic information in advanced chronic liver disease
    Bauer, David J. M.
    Yang, Zhenwei
    Koeck, Fiona
    Fritz, Laurenz
    Hofer, Benedikt
    Balcar, Lorenz
    Hartl, Lukas
    Jachs, Mathias
    Stopfer, Katharina
    Bucsics, Theresa
    Simbrunner, Benedikt
    Scheiner, Bernhard
    Trauner, Michael
    Mandorfer, Mattias
    Reiberger, Thomas
    Semmler, Georg
    JOURNAL OF HEPATOLOGY, 2023, 78 : S831 - S832
  • [45] Hepatitis B vaccination of patients with chronic liver disease
    Keeffe, EB
    Krause, DS
    LIVER TRANSPLANTATION AND SURGERY, 1998, 4 (05): : 437 - 439
  • [46] Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B
    Marcellin, Patrick
    Ziol, Marianne
    Bedossa, Pierre
    Douvin, Catherine
    Poupon, Raoul
    de Ledinghen, Victor
    Beaugrand, Michel
    LIVER INTERNATIONAL, 2009, 29 (02) : 242 - 247
  • [47] Patients With Chronic Hepatitis B Should Be Screened for Hepatocellular Carcinoma Regardless of Liver Stiffness Measurement
    Sultanik, Philippe
    Sogni, Philippe
    Meritet, Jean-Francois
    Pol, Stanislas
    Mallet, Vincent
    HEPATOLOGY, 2016, 63 (02) : 672 - 672
  • [48] Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients
    Wong, Vincent Wai-Sun
    Lampertico, Pietro
    de Ledinghen, Victor
    Chang, Pik Eu
    Kim, Seung Up
    Chen, Yongpeng
    Chan, Henry Lik-Yuen
    Mangia, Giampaolo
    Foucher, Juliette
    Chow, Wan Cheng
    Ahn, Sang Hoon
    Hou, Jinlin
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (05) : 1448 - 1456
  • [49] DIAGNOSTIC POTENTIAL OF LIVER STIFFNESS MEASUREMENT IN CHRONIC HEPATITIS B COMBINED WITH METABOLIC-ASSOCIATED FATTY LIVER DISEASE
    Li, Jia
    Liu, Jie
    Zhai, Lu
    Zhao, Li-Li
    Wang, Jing
    Shi, Rui-Fang
    Wang, Chun-yan
    Li, Jia
    HEPATOLOGY, 2021, 74 : 950A - 950A
  • [50] OPTIMIZED CUTOFF OF LIVER STIFFNESS MEASUREMENT FOR RULING IN SIGNIFICANT FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B
    Zhang, Zhiyi
    Zhu, Li
    Liu, Xingxiang
    Wang, Jian
    Zhang, Shaoqiu
    Yan, Xiaomin
    Qiu, Yuanwang
    Li, Jie
    Huang, Rui
    Wu, Chao
    HEPATOLOGY, 2023, 78 : S436 - S437